Antigenic structure of the human coronavirus OC43 spike reveals exposed and occluded neutralizing epitopes
© 2022. The Author(s)..
Human coronavirus OC43 is a globally circulating common cold virus sustained by recurrent reinfections. How it persists in the population and defies existing herd immunity is unknown. Here we focus on viral glycoprotein S, the target for neutralizing antibodies, and provide an in-depth analysis of its antigenic structure. Neutralizing antibodies are directed to the sialoglycan-receptor binding site in S1A domain, but, remarkably, also to S1B. The latter block infection yet do not prevent sialoglycan binding. While two distinct neutralizing S1B epitopes are readily accessible in the prefusion S trimer, other sites are occluded such that their accessibility must be subject to conformational changes in S during cell-entry. While non-neutralizing antibodies were broadly reactive against a collection of natural OC43 variants, neutralizing antibodies generally displayed restricted binding breadth. Our data provide a structure-based understanding of protective immunity and adaptive evolution for this endemic coronavirus which emerged in humans long before SARS-CoV-2.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Nature communications - 13(2022), 1 vom: 25. Mai, Seite 2921 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Chunyan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 27.05.2022 Date Revised 13.11.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-022-30658-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34136519X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34136519X | ||
| 003 | DE-627 | ||
| 005 | 20231226011617.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-022-30658-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1137.xml |
| 035 | |a (DE-627)NLM34136519X | ||
| 035 | |a (NLM)35614127 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Chunyan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antigenic structure of the human coronavirus OC43 spike reveals exposed and occluded neutralizing epitopes |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.05.2022 | ||
| 500 | |a Date Revised 13.11.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a Human coronavirus OC43 is a globally circulating common cold virus sustained by recurrent reinfections. How it persists in the population and defies existing herd immunity is unknown. Here we focus on viral glycoprotein S, the target for neutralizing antibodies, and provide an in-depth analysis of its antigenic structure. Neutralizing antibodies are directed to the sialoglycan-receptor binding site in S1A domain, but, remarkably, also to S1B. The latter block infection yet do not prevent sialoglycan binding. While two distinct neutralizing S1B epitopes are readily accessible in the prefusion S trimer, other sites are occluded such that their accessibility must be subject to conformational changes in S during cell-entry. While non-neutralizing antibodies were broadly reactive against a collection of natural OC43 variants, neutralizing antibodies generally displayed restricted binding breadth. Our data provide a structure-based understanding of protective immunity and adaptive evolution for this endemic coronavirus which emerged in humans long before SARS-CoV-2 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Epitopes |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 700 | 1 | |a Hesketh, Emma L |e verfasserin |4 aut | |
| 700 | 1 | |a Shamorkina, Tatiana M |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Wentao |e verfasserin |4 aut | |
| 700 | 1 | |a Franken, Peter J |e verfasserin |4 aut | |
| 700 | 1 | |a Drabek, Dubravka |e verfasserin |4 aut | |
| 700 | 1 | |a van Haperen, Rien |e verfasserin |4 aut | |
| 700 | 1 | |a Townend, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a van Kuppeveld, Frank J M |e verfasserin |4 aut | |
| 700 | 1 | |a Grosveld, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Ranson, Neil A |e verfasserin |4 aut | |
| 700 | 1 | |a Snijder, Joost |e verfasserin |4 aut | |
| 700 | 1 | |a de Groot, Raoul J |e verfasserin |4 aut | |
| 700 | 1 | |a Hurdiss, Daniel L |e verfasserin |4 aut | |
| 700 | 1 | |a Bosch, Berend-Jan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 13(2022), 1 vom: 25. Mai, Seite 2921 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g number:1 |g day:25 |g month:05 |g pages:2921 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-022-30658-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |e 1 |b 25 |c 05 |h 2921 | ||